Utah’s business landscape is rich with professionals who have le...Read More
Social Media and Employers: Friends or Enemies?
The Case for HSAs
Time to Show Up
Make a Move
In the Lab
Rent to Own
Back from the Dead
A Breath of Fresh Air
Travel & Tourism
PerMIT works—that’s the broad message of the first data to emerge from trials of the revolutionary dosing decision support software. PerMIT is short for Personalized Medicine Interface Tool, the first in a series of interactive longitudinal management tools developed by PGXL Laboratories.
In a study published in Thrombosis and Haemostasis, patients treated using PerMIT/Warfarin reached stable and therapeutic response to the commonly prescribed anticoagulant warfarin (Coumadin) in a shorter time than those treated conventionally (clinicaltrials.gov, NCT00993200). The study was small – 26 patients – but the results were striking: a substantial reduction in the time to stability within the target therapeutic range, an improvement in the percentage of time within the therapeutic interval, and a decrease in the frequency of dose adjustments necessary to maintain patients in warfarin’s safe and effective range – all as a result of guidance provided by PerMIT software.
“This study demonstrates that PerMIT is effective,” said Dr. Mark Linder, executive vice president of PGXL and co-inventor of PerMIT. “Further studies will help us quantify the benefits.”
PerMIT is based on algorithms that use individual genetic and other patient data to provide treatment guidance in real time. PerMIT/Warfarin, for example, calculates an optimal therapeutic path based on variations in two genes, CYP2C9 and VKORC1, which control the metabolism and action of the drug. PerMIT’s modeling capability gives physicians the power to test specific adjustments without putting the patient at risk, and then to continually adjust treatment based on actual performance compared to the chosen model.
PerMIT/Warfarin is the first of several Companion Informatics being developed by PGXL. A Companion Informatic is an application designed to be used in concert with a drug, or to address diagnosis and treatment of a particular medical problem. The continuously updated algorithm is based on the latest medical research, enabling physicians to craft the optimal treatment path for individual patients.
PerMIT was developed at the University of Louisville. ARUP Laboratories, a national clinical and anatomic pathology reference laboratory in Salt Lake City, was a key underwriter of PerMIT and is committed to the use of genetic information to improve the care of its patients. ARUP was the first lab to use PerMIT clinically to estimate the warfarin dose needs for individual patients.
PerMIT/Warfarin is currently being used in another clinical trial at the University of Utah.